Results 81 to 90 of about 72,428 (200)

Mechanism of Lenvatinib Resistance via Exosomal miRNA‐132/Nrf2 Axis in Hepatocellular Carcinoma

Annals of Gastroenterological Surgery, EarlyView.
Exosomal miRNA‐132 from LVT‐res HCC cells activated Nrf2 expression through the PTEN/GSK3β pathway in recipient cells. This cascade could induce drug resistance in non‐resistant HCC cells in the TME. ABSTRACT Introduction Lenvatinib is a multiple receptor tyrosine kinase inhibitor and a first‐line targeted therapy for hepatocellular carcinoma (HCC ...
Chie Takasu, Chiharu Nakasu, Yu Saito, Yuji Morine, Tetsuya Ikemoto, Shinichiro Yamada, Hiroki Teraoku, Mitsuo Shimada   +7 more
wiley   +1 more source

Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma

Pharmaceuticals, 2021
Hepatocellular carcinoma (HCC) recurrence after liver transplantation occurs in approximately 20% of patients. Most of these patients use immunosuppressant drugs.
Koen G. A. M. Hussaarts, Leni van Doorn, Sander Bins, Dave Sprengers, Peter de Bruijn, Roelof W. F. van Leeuwen, Stijn L. W. Koolen, Teun van Gelder, Ron H. J. Mathijssen   +8 more
doaj   +1 more source

Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.

JAMA Oncology, 2019
Importance Sorafenib is the first-line treatment for hepatocellular carcinoma with portal vein invasion; however, it has shown unsatisfactory survival benefit. Sorafenib plus hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, fluorouracil, and
M. He, Qi-Jiong Li, Ruhai Zou, Jingxian Shen, Wanqiang Fang, Guosheng Tan, Yuanmin Zhou, Xiaoping Wu, Li Xu, Wei Wei, Yong Le, Zhongguo Zhou, Ming Zhao, Ying Guo, R. Guo, Minshan Chen, M. Shi   +16 more
semanticscholar   +1 more source

Genomics Review of Selective RET Inhibitors Sensitivity in Thyroid Cancer Clinical Trials

American Journal of Medical Genetics Part C: Seminars in Medical Genetics, EarlyView.
ABSTRACT RET gene is a driver of thyroid cancer (TC) tumorigenesis. The incidence of TC has increased worldwide in the last few decades, both in medullary and follicular‐derived subtypes. Several drugs, including multikinase and selective inhibitors, have been explored.
Sara Gil‐Bernabé, Lucía García‐DeLaFuente, Alejandro García‐Álvarez, Ginesa García‐Rostán, Jaume Capdevila, Jorge Hernando   +5 more
wiley   +1 more source

SMYD3 induces sorafenib resistance by activating SMAD2/3-mediated epithelial-mesenchymal transition in hepatocellular carcinoma

iScience, 2023
Summary: Drug resistance prominently hampers the effects of systemic therapy of sorafenib to hepatocellular carcinoma (HCC). Epigenetics have critical regulatory roles in drug resistance.
Shanshan Wang, Xin You, Xiaoshu Liu, Fengwei Zhang, Hongjuan Zhou, Xuechai Shang, Long Cai   +6 more
doaj   +1 more source

Approaches to Enhance Photodynamic Therapy of Lung Cancer: Potential Application of Nanoparticles

Advanced NanoBiomed Research, EarlyView.
Bioactive ligand‐targeted nanocarriers can accommodate functionalization with numerous targeting ligands for effective delivery of photosensitizers (PSs) within targeted photodynamic therapy. Various targeting moieties including peptides, antibodies, carbohydrates, aptamers, proteins, and PS anticancer molecules can be attached to nanomaterials.
Nokuphila Winifred Nompumelelo Simelane, Heidi Abrahamse   +1 more
wiley   +1 more source

Analysis of Sorafenib Outcome: Focusing on the Clinical Course in Patients with Hepatocellular Carcinoma. [PDF]

PLoS ONE, 2016
Treatment outcomes of sorafenib therapy may greatly vary depending not only on tumor spread but also on past clinical processes prior to sorafenib therapy and timing of sorafenib administration in the past clinical course of hepatocellular carcinoma (HCC)
Sadahisa Ogasawara, Tetsuhiro Chiba, Yoshihiko Ooka, Eiichiro Suzuki, Masanori Inoue, Toru Wakamatsu, Akinobu Tawada, Osamu Yokosuka   +7 more
doaj   +1 more source

Fostamatinib and the risk of acute aortic dissection in immune thrombocytopenia

British Journal of Clinical Pharmacology, EarlyView.
Immune thrombocytopenia (ITP) is a rare autoimmune disorder characterized by platelet destruction. While most patients respond to first‐ or second‐line therapies, a small subset is multirefractory. Fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, is a therapeutic option in these cases.
Paul Dalmas, Alexis Theron, Rita Badaoui, Stéphane Zaffran, Rayid Mchinda, Joelle Micallef, Nicolas Schleinitz, Mikael Ebbo   +7 more
wiley   +1 more source

Mechanism and role of regulated cell death in tumor immunity and immunotherapy

Cancer Communications, EarlyView.
Abstract Cancer immune checkpoint inhibitors (ICIs) have brought breakthroughs, but only about one‐third of cancer patients benefit from ICIs. In recent years, targeting non‐apoptotic regulated cell death (RCD) subtypes, such as ferroptosis, necroptosis, autophagy, cuproptosis, and pyroptosis, has emerged as a novel strategy in cancer therapy due to ...
Jingwen Hu, Yan Li, Bingjie Lian, Yitao Mao, Luqing Zhao   +4 more
wiley   +1 more source

The Monoclonal Antibody CH12 Enhances the Sorafenib-Mediated Growth Inhibition of Hepatocellular Carcinoma Xenografts Expressing Epidermal Growth Factor Receptor Variant III

Neoplasia: An International Journal for Oncology Research, 2012
The multikinase inhibitor sorafenib is the first oral agent to show activity against human hepatocellular carcinoma (HCC). Although the clinical application of sorafenib has shown good tolerability in the studied populations, it also causes multiple ...
Yaqiong Yang, Hua Jiang, Huiping Gao, Juan Kong, Pengwei Zhang, Suwen Hu, Bizhi Shi, Pengfei Zhang, Ming Yao, Zonghai Li   +9 more
doaj   +1 more source